title: Anti-atherogenic property of ferulic acid in apolipoprotein E-deficient mice fed Western diet: comparison with clofibrate.
abstract: Anti-atherogenic effect of ferulic acid (0.02%, w/w) was investigated in comparison with the clofibrate (0.02%, w/w) in apolipoprotein E-deficient (apo E(-/-)) mice fed Western diet. Concentrations of total cholesterol (total-C), apolipoprotein B (apo B) in the plasma and epididymal adipose tissue weight were significantly lower in the ferulic acid and clofibrate supplemented groups compared to the control group. The ratio of apo B to apo A-I was also significantly lower in those groups than in the control group. Activities of hepatic ACAT and HMG-CoA reductase were only significantly lower in the ferulic acid and clofibrate groups, respectively than in the control group. The numbers of mice that exhibited aortic fatty plaque were 8/10 in control groups vs. 0/10 in the ferulic acid or clofibrate group. The activities of anti-oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and paraoxonase) in the hepatocyte and erythrocyte were significantly higher in the ferulic acid group than in the control group. In contrast, hepatic TBARS level was only markedly lower in the ferulic acid group. These results provide a new insight into the anti-atherogenic property of ferulic acid in the apo E(-/-) mice fed a Western diet.
authors.affiliation: Department of Food Science and Nutrition, Center for Food and Nutritional Genomics, Kyungpook National University, Daegu 702-701, South Korea.
authors.forename: E Y
authors.initials: EY
authors.lastname: Kwon
authors.forename: G M
authors.initials: GM
authors.lastname: Do
authors.forename: Y Y
authors.initials: YY
authors.lastname: Cho
authors.forename: Y B
authors.initials: YB
authors.lastname: Park
authors.forename: S M
authors.initials: SM
authors.lastname: Jeon
authors.forename: M S
authors.initials: MS
authors.lastname: Choi
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001057:Apolipoproteins E / Q000235:genetics* / Q000502:physiology; D043303:Aryldialkylphosphatase / Q000378:metabolism; D050197:Atherosclerosis / Q000473:pathology / Q000517:prevention & control*; D002994:Clofibrate / Q000494:pharmacology*; D003373:Coumaric Acids / Q000494:pharmacology*; D004032:Diet; D004435:Eating / Q000187:drug effects; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009929:Organ Size / Q000187:drug effects; D002785:Sterol O-Acyltransferase / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D001057:Apolipoproteins E; D003373:Coumaric Acids; D008055:Lipids; C004999:ferulic acid; D006903:Hydroxymethylglutaryl CoA Reductases; D002785:Sterol O-Acyltransferase; D043303:Aryldialkylphosphatase; D002994:Clofibrate